{"classes":[{"categories":[{"measurements":[{"comment":"No data collected due to censoring prior to PD.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Due to censoring prior to PD, median not collected as per Statistical Analysis Plan.","groupId":"OG001","lowerLimit":"0.49","upperLimit":"8","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"TTP is defined as the time from the date of study enrollment to the date of objectively determined progressive disease. TTP will be censored at the date of the last objective progression free disease assessment.","dispersionType":"Full Range","groups":[{"description":"Cohort 1. 100 mg tabalumab (LY2127399) intravenously (IV) on day 1 of each cycle. Bortezomib (BTZ), 1.3 milligram per square meter (mg/m\\^2), IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dexamethasone (Dex), 20 mg/day, on day of and day after BTZ.","id":"OG000","title":"100 mg Tabalumab+BTZ IV+Dex"},{"description":"Cohort 2. 300 mg tabalumab (LY2127399) IV on day 1 of each cycle. BTZ, 1.3 mg/m\\^2, IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ subcutaneously or intravenously (SC, IV respectively).","id":"OG001","title":"300 mg Tabalumab+BTZ +Dex"}],"paramType":"MEDIAN","populationDescription":"All participants who received at least 1 dose of study drug and didn't have AEs . 300 mg tabalumab group administered BTZ IV or SC data were combined per protocol, BTZ was a supplemental therapy for participants. Participants that were censored prior to PD and not included in analysis:100 mg tabalumab n=4, 300 mg tabalumab n=8.","reportingStatus":"POSTED","timeFrame":"Baseline to date of Progressive Disease (up to 455 days)","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"months"}